Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289091 | 0.88 | LATS1 (0.36) | ELANEHTTLATS1LATS2 | |
| SCHEMBL14289088 | 0.79 | GPR3 (0.43) | ELANEHTTLRRK2 | |
| SCHEMBL22792591 | 0.77 | — | — | |
| SCHEMBL11200595 | 0.69 | GPR3 (0.41) | NCOA3HTT | |
| SCHEMBL22793043 | 0.67 | DHODH (0.33) | LATS1LATS2 | |
| SCHEMBL22793014 | 0.67 | MAPK10 (0.33) | NCOA3HTTLATS1LATS2AAK1 | |
| SCHEMBL14289092 | 0.65 | LATS1 (0.32) | LATS1LATS2 | |
| SCHEMBL14289093 | 0.65 | CYP1A2 (0.31) | — | |
| SCHEMBL22792959 | 0.64 | LATS1 (0.35) | LATS1LATS2 | |
| SCHEMBL14059374 | 0.61 | LRRK2 (0.56) | NCOA3HTTLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | ELANE 3031/4885NCOA3 2085/4885HTT 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.